Oncology Business Management | Specialty

Role of Rebiopsy and ctDNA Testing at Progression of mCRC

February 25th 2020

Molecular Status and Subsequent Therapies in mCRC

February 25th 2020

Initial Systemic Therapy for Metastatic Colorectal Cancer

February 25th 2020

Continuum of Care in Metastatic Colorectal Cancer

February 25th 2020

ASCO Identifies Additional Ways to Improve Hazardous Drug Safety

February 24th 2020

The United States Pharmacopeial Convention (USP) General Chapter is a good start for improving the protection of healthcare workers exposed to hazardous drugs, but more studies and safety protocols are needed, according to an American Society of Clinical Oncology (ASCO) expert panel that evaluated USP and various other guidelines in a report last year.

Value-Based Care With Two-Sided Risk a Preference in Upcoming Oncology Care Model

February 13th 2020

Oncology practices that are participating in the Centers for Medicare & Medicaid Innovation’s Oncology Care Model are willing to take on two-sided risk with value-based care and shift from a fee-for-service approach.

Oncology Payment Models Fall Short of Desired Goals

February 5th 2020

There is a year and a half remaining in the life of the Oncology Care Model, and although the Centers for Medicare & Medicaid Services has leapt forward with a vision for the next-generation model of care Oncology Care First, many stakeholders feel that the Oncology Care Model is more than enough to think about right now.

FDA Approval in HER2+ Breast Cancer, Priority Review in NSCLC, and More

February 1st 2020

Review Period Extended in GIST, Disappointing Findings in Lung Cancer, and More

February 1st 2020

Treating Unresectable HCC in the Community

February 1st 2020

Sequencing With I-O Combinations in Unresectable HCC

February 1st 2020

Emerging I-O Combination Trials in Unresectable HCC

February 1st 2020

IMbrave150 in Unresectable HCC

February 1st 2020

Immunotherapy in Unresectable HCC

February 1st 2020

Challenges With Novel Treatment Strategies

February 1st 2020

The COSMIC-312 Phase III and Other Notable Trials

February 1st 2020

IMbrave150 Phase III Design, Results, and Practical Implications

February 1st 2020

The Impact of Liver Pathobiology on HCC Treatment Approach

February 1st 2020

Dr. Marshall on Physician Burnout in Oncology

January 31st 2020

John L. Marshall, MD, discusses physician burnout in oncology.

Practices Make Surprise Decision on OCM Risk

January 30th 2020

Many practices enrolled in the Oncology Care Model were expected to drop out of the value-based model rather than take on 2-sided risk, which would entail upside and downside financial exposure.